Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients With BCR-ABL Tyrosine Kinase Inhibitor Responsive Ph+ Acute Leukemia ? A Multi-center Trial

NCT00036738 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT00036738
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00036738 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients With BCR-ABL Tyrosine Kinase Inhibitor Responsive Ph+ Acute Leukemia ? A Multi-center Trial
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
July 13, 2001
Completion date
May 31, 2018
Enrollment
28 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

adult acute lymphoblastic leukemia in remission, adult b acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); bcr-abl1, blastic phase, childhood acute lymphoblastic leukemia in remission, childhood b acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); bcr-abl1, chronic myelogenous leukemia, bcr-abl1 positive, chronic phase of disease, recurrent adult acute lymphoblastic leukemia, recurrent childhood acute lymphoblastic leukemia, recurrent disease